In a development that has drawn international attention to the illicit ketamine trade, the personal assistant to the late actor Matthew Perry has been sentenced in a Los Angeles federal court. Kenneth Iwamasa, 59, pleaded guilty to one count of conspiracy to distribute ketamine, resulting in Perry’s fatal overdose in October 2023. The sentencing, handed down today, marks a critical juncture in the investigation into the supply chain that fuelled the actor’s addiction. Meanwhile, British drug enforcement agencies are intensifying their monitoring of ketamine trafficking, recognising the transnational implications of this case.
Iwamasa, who administered multiple ketamine injections to Perry on the day of his death, received a 12-month prison term followed by three years of supervised release. The sentence, significantly shorter than the maximum of 10 years, reflects his cooperation with authorities and his role as a conduit rather than a high-level distributor. Court documents reveal that Iwamasa obtained the ketamine from a network of dealers, including Dr. Salvador Plasencia, a physician charged with distributing the drug outside legitimate medical channels. Plasencia is scheduled for trial next year and faces a potential life sentence if convicted.
The ketamine involved in Perry’s death was diverted from legitimate pharmaceutical supplies, a trend that has alarmed regulators on both sides of the Atlantic. In the United Kingdom, the National Crime Agency (NCA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have stepped up surveillance of ketamine imports and prescription patterns. According to NCA data, seizures of illicit ketamine have increased by 40% since 2022, with much of the supply originating from India and China. British authorities are now working with US counterparts to trace the financial and logistical networks that enabled the diversion.
This case highlights a broader crisis: the rising recreational use of ketamine, particularly among younger demographics. Ketamine, once primarily used as an anaesthetic and for treatment-resistant depression, has become a popular party drug. In the UK, deaths linked to ketamine have tripled over the past five years, with many victims unknowingly consuming potent batches laced with fentanyl. The NCA has warned that the drug’s popularity is fuelling a parallel market for medical-grade ketamine, stolen or repurposed from veterinary clinics and hospitals.
The Perrys case has also reignited debate about the responsibilities of pharmaceutical companies and healthcare providers in preventing diversion. Ketamine is a Schedule 2 controlled substance in the US and a Class B drug in the UK, but regulatory loopholes persist. For instance, telemedicine platforms in the US have been criticised for prescribing ketamine without adequate safeguards. British regulators are now reviewing similar remote prescribing practices to ensure they do not inadvertently contribute to abuse.
As Iwamasa begins his sentence, British enforcement officials are pursuing leads on a UK-based ketamine trafficking ring believed to have supplied the American distributors. The NCA has confirmed that multiple arrests have been made in connection with the case, though details remain under wraps. The agency has also issued a public alert about the dangers of non-medical ketamine use, emphasising the risks of respiratory depression and bladder damage.
For scientists and public health experts, this tragedy underscores the need for evidence-based policies that balance access to therapeutic drugs with rigorous enforcement. The data are clear: ketamine has legitimate medical applications, but its misuse carries severe costs. As Dr. Stephen Miller, a pharmacologist at the University of Cambridge, notes: ‘We are seeing the classic pattern of a beneficial drug becoming a public health liability due to inadequate controls. The Matthew Perry case is a wake-up call for regulators worldwide.’
In the aftermath of the sentencing, the Perry family has called for increased funding for addiction treatment and stricter oversight of controlled substances. Their statement, released this morning, urged lawmakers to close the gaps that allowed a doctor and a personal assistant to facilitate a fatal overdose. The NCA, for its part, has pledged to continue its collaboration with US agencies, aiming to dismantle the supply chains that enable tragedies like this one.
The intersection of celebrity, addiction, and international drug trafficking is a complex narrative. But beneath the headlines lies a simple physical reality: molecules of ketamine, diverted from their intended use, caused the death of a human being. As British officials monitor the trade, the hope is that rigorous enforcement and scientific scrutiny will prevent further losses.
